CA-DENODO
21.3.2022 09:02:09 CET | Business Wire | Press release
Denodo , the leader in data management, today announced that its subscription license revenue grew more than 50 percent year-over-year, as the company moved close to becoming a 100 percent subscription-based revenue business. While new customer acquisitions and existing customer expansion remained strong and steady year-over-year, Denodo’s cloud marketplace presence encountered the fastest growth with more than 300 transactions in 2021.
Denodo customers’ positive sentiment about its product, services, and support was once again captured as part of the Gartner Peer Insights reviews and, as a result, Denodo has again been recognized as a Customer's Choice in the Gartner Peer Insights “Voice of the Customer”: Data Integration Tools , 28 January 2022. With an overall rating of 4.4 out of 5, Denodo is one of the only three Gartner® Magic Quadrant™ for Data Integration Tools Leaders to receive Customers’ Choice for 2022 and is the third highest rated data integration vendor in the report. Denodo was also positioned as a Leader for the Second Consecutive Year in the 2021 Gartner® Magic Quadrant™ for Data Integration Tools . During the same year, Denodo customers and Denodo Platform were bestowed with numerous awards and recognitions, such as TDWI Best Practices Award, Ventana Research Digital Leadership Award, and DBTA Readers' Choice Awards, to name a few.
During 2021, Denodo added important brand names to its already stellar global customer roster, including Credit Suisse, Deutsche Bank, Toyota Financial Services, Johnson & Johnson, and Goldwind. During the same period, Denodo Platform version 8, which was launched in 2020 to offer enterprises the ability to deploy enterprise grade logical data fabric, added some major capabilities including AI & Recommendations and Advanced Semantics. These new additions help enterprise data and analytics teams automate frequently used data management functions, improve collaboration between data stewards and business users, and secure data access.
The Company extended its worldwide footprint to 25 offices spanning 20 countries, including new offices in South Korea, Sweden, Netherlands and Belgium. During the same year, strategic technology and consulting alliances also intensified as marked by a 56 percent increase in new signed partner agreements and significant growth within current partnerships, bringing a 192 percent increase in revenue from this important channel.
“Every company rooted in making data-driven business decisions is realizing that it is impractical to move all their data in a single repository such as a cloud data lake or cloud data warehouse,” said Angel Viña, founder and CEO of Denodo. “That is exactly why they selected Denodo Platform to build their logical data fabric to integrate, manage and deliver their enterprise data to business stakeholders. We thank our partners and customers alike for their continued support for our platform and we are looking forward to helping hundreds of new customers who are looking to make insights-driven business decisions and support their enterprise data across cloud and regional boundaries.”
Please Tweet: #dataintegration leader @denodo announces double-digit revenue growth and strong momentum in customer acquisition through #amazon #google and #azure marketplaces
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using logical approach to enable self-service BI, advanced analytics, hybrid/multi-cloud integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprise and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom